504 related articles for article (PubMed ID: 12627516)
21. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts.
Helgstrand JT; Røder MA; Klemann N; Toft BG; Lichtensztajn DY; Brooks JD; Brasso K; Vainer B; Iversen P
Cancer; 2018 Jul; 124(14):2931-2938. PubMed ID: 29723398
[TBL] [Abstract][Full Text] [Related]
22. Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
Miller EA; Pinsky PF; Black A; Andriole GL; Pierre-Victor D
Prostate; 2018 Aug; 78(11):830-838. PubMed ID: 29667217
[TBL] [Abstract][Full Text] [Related]
23. Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.
Feuer EJ; Merrill RM; Hankey BF
J Natl Cancer Inst; 1999 Jun; 91(12):1025-32. PubMed ID: 10379965
[TBL] [Abstract][Full Text] [Related]
24. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Negoita S; Feuer EJ; Mariotto A; Cronin KA; Petkov VI; Hussey SK; Benard V; Henley SJ; Anderson RN; Fedewa S; Sherman RL; Kohler BA; Dearmon BJ; Lake AJ; Ma J; Richardson LC; Jemal A; Penberthy L
Cancer; 2018 Jul; 124(13):2801-2814. PubMed ID: 29786851
[TBL] [Abstract][Full Text] [Related]
25. PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.
Wachtel MS; Nelius T; Haynes AL; Dahlbeck S; de Riese W
Prostate; 2013 Sep; 73(12):1365-9. PubMed ID: 23649537
[TBL] [Abstract][Full Text] [Related]
26. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer incidence and mortality rates and trends in the United States and Canada.
McDavid K; Lee J; Fulton JP; Tonita J; Thompson TD
Public Health Rep; 2004; 119(2):174-86. PubMed ID: 15192905
[TBL] [Abstract][Full Text] [Related]
28. Racial disparities in late-stage prostate cancer: a SEER analysis 2005-2015.
Rodriguez S; Sparks AD; Zhou H; Amdu RL; Lin J
Can J Urol; 2019 Oct; 26(5):9946-9951. PubMed ID: 31629445
[TBL] [Abstract][Full Text] [Related]
29. Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey.
Mariotto AB; Etzioni R; Krapcho M; Feuer EJ
Cancer; 2007 May; 109(9):1877-86. PubMed ID: 17372918
[TBL] [Abstract][Full Text] [Related]
30. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
31. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity.
Powell IJ; Bock CH; Ruterbusch JJ; Sakr W
J Urol; 2010 May; 183(5):1792-6. PubMed ID: 20299055
[TBL] [Abstract][Full Text] [Related]
32. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
Kaur D; Ulloa-Pérez E; Gulati R; Etzioni R
Cancer; 2018 Apr; 124(8):1752-1759. PubMed ID: 29370459
[TBL] [Abstract][Full Text] [Related]
33. Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration.
Wood HM; Reuther AM; Gilligan TD; Kupelian PA; Modlin CS; Klein EA
J Urol; 2007 Oct; 178(4 Pt 1):1271-6. PubMed ID: 17698101
[TBL] [Abstract][Full Text] [Related]
34. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.
Godley PA; Schenck AP; Amamoo MA; Schoenbach VJ; Peacock S; Manning M; Symons M; Talcott JA
J Natl Cancer Inst; 2003 Nov; 95(22):1702-10. PubMed ID: 14625261
[TBL] [Abstract][Full Text] [Related]
35. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
36. Exploring causes for declining prostate cancer mortality rates in the United States.
Colli JL; Amling CL
Urol Oncol; 2008; 26(6):627-33. PubMed ID: 18367111
[TBL] [Abstract][Full Text] [Related]
37. The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach.
Hanson HA; Martin C; O'Neil B; Leiser CL; Mayer EN; Smith KR; Lowrance WT
J Urol; 2019 Dec; 202(6):1209-1216. PubMed ID: 31246547
[TBL] [Abstract][Full Text] [Related]
38. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates.
Feuer EJ; Mariotto A; Merrill R
Cancer; 2002 Aug; 95(4):870-80. PubMed ID: 12209732
[TBL] [Abstract][Full Text] [Related]
39. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.
Wang SS; Sherman ME; Hildesheim A; Lacey JV; Devesa S
Cancer; 2004 Mar; 100(5):1035-44. PubMed ID: 14983500
[TBL] [Abstract][Full Text] [Related]
40. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment.
Butler EN; Kelly SP; Coupland VH; Rosenberg PS; Cook MB
Br J Cancer; 2020 Aug; 123(3):487-494. PubMed ID: 32433602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
